We use cookies to improve site performance and enhance your user experience. If you'd like to disable cookies on this device, please see our cookie management page.
If you close this message or continue to use this site, you consent to our use of cookies on this devise in accordance with our cookie policy, unless you disable them.

Close

registration required

or
for more website access

This content can only be viewed by subscribers and registered users of Investors Chronicle.

Subscribe or register free today

GSK rebuffed

GlaxoSmithKline has been knocked back in its second attempt at acquiring Human Genome Sciences (HGS) in a $13-a-share deal that values the US-based biotechnology company at $2.6bn (£1.6bn). GSK's attempt at taking over HGS is a standard ploy in the pharma industry: buying out a partner company, rather than handing over money in royalties. GSK may yet come back with an improved offer and investors can take comfort that, despite the initial outlay, the deal would add to earnings almost immediately. It further bolsters the buy case for GSK through its ability to diversify its operations.

registration required

visible-status-Subscription-Only story-url-GSK Update 19 Apr 2012.xml

By Julian Hofmann,
19 April 2012

Print this article
Comments

More tips and updates for this share

Share Price

More by Julian Hofmann

IC columnists

Simon Thompson

Simon Thompson

Winning stock and trading ideas from the creator of the Bargain Portfolio

The Trader

The Trader

Technical analysis and market calls from our in-house charting expert

Mr Bearbull

Mr Bearbull

Sound advice on running portfolios from an experienced commentator

Smart Money

Smart Money

Practical advice to help you plan your future

Chris Dillow

Chris Dillow

Incisive economic commentary plus thoughts on investor behaviour

Property Matters

Property Matters

Comment on the ups and downs of property investments, with a particular focus on the perennially popular world of buy to let

The Editor

The Editor

Commentary on markets, world affairs and everything to do with investing

Chronic Investor Blog

Chronic Investor Blog

Our light-hearted take on the world of investing

Advertiser reports

Register today and get...

Register today and get...
Please note terms & conditions apply